0000000000269750

AUTHOR

Francesco Albano

showing 6 related works from this author

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN…

2020

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely…

2019-20 coronavirus outbreakCancer ResearchPneumonia ViralDiseasesSevere Acute Respiratory Syndromemedicine.disease_causeBetacoronavirusMyeloproliferative DisordersNeoplasmsSurveys and QuestionnairesPandemicmedicineHumansPandemicsCoronavirusPhiladelphia negativeMyeloproliferative DisordersbiologySARS-CoV-2business.industryHealth careCOVID-19Hematologymedicine.diseasebiology.organism_classificationVirologyCoronavirusPneumoniaItalyOncologyPerspectiveCoronavirus InfectionsbusinessCoronavirus InfectionsBetacoronavirusBetacoronavirus COVID-19 Humans Italy SARS-CoV-2 Surveys and Questionnaires Coronavirus Coronavirus Infections Myeloproliferative Disorders Neoplasms Pandemics Pneumonia Viral Severe Acute Respiratory Syndrome
researchProduct

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

2019

medicine.medical_specialtyMyeloproliferative Disordersbusiness.industryHematologyMyeloproliferative neoplasm surevymedicine.diseaseClinical PracticeSettore MED/15 - MALATTIE DEL SANGUEItalyHematologic NeoplasmsSurveys and QuestionnairesFamily medicinemedicineHumansMyeloproliferative NeoplasmsGuideline AdherencebusinessMyeloproliferative neoplasm
researchProduct

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

2022

Simple Summary IDH1/2 mutations are a common event in acute myeloid leukemia (AML) and represent a therapeutic target. We designed the GIMEMA AML1516 observational protocol to examine the prevalence of IDH1/2 mutations and the associations between IDH mutations and clinico-biological parameters in a cohort of Italian patients affected by AML. By analyzing 284 consecutive adult AML patients, we confirmed that IDH1 and IDH2 mutations are frequently detected-14% and 18%, respectively-at diagnosis. IDH1/2 mutations were significantly associated with an inferior performance status and non-complex karyotype when compared to IDH1/2-WT. With regards to the outcome, in the subset of IDH1/2-mutated p…

DH1Cancer ResearchOncologyAMLAML DH1 IDH2 prevalence prognosisprevalenceIDH2prognosisSettore MED/15AML; DH1; IDH2; prevalence; prognosis
researchProduct

Outcome of patients with CML treated with dasatinib or nilotinib after failure of second prior TKIs.

2010

Abstract Abstract 2294 Background. The TKIs Nilotinib and Dasatinib offer additional therapeutic options for patients with CML who are resistant or intolerant to Imatinib. These agents, active against the majority of Imatinib resistant BCR-ABL mutated clones, have a different pattern of kinase target selectivity, pharmacokinetics parameters, cell uptake, efflux properties and adverse events profiles. Preliminary results suggest that some patients may respond to a second TKI used as third line therapy, but little is known about the long term benefit of such an approach.Aim of this collaborative Italian study was to verify the response (rate and duration) and the clinical outcome in patients …

Oncologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyComplete blood countAlpha interferonImatinibCell BiologyHematologyGene mutationBiochemistrySurgeryDasatinibNilotinibMedian follow-upInternal medicinemedicineAdverse effectbusinessmedicine.drug
researchProduct

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

2020

2019-20 coronavirus outbreakPediatricsmedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)EpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralPhiladelphia chromosomeSeverity of Illness IndexMyeloproliferative diseaseBetacoronavirusMyeloproliferative DisordersLeukemia Myelogenous Chronic BCR-ABL PositiveCorrespondenceNitrilesmedicineHumansPhiladelphia ChromosomeBetacoronavirus COVID-19 Coronavirus Infections Cross-Sectional Studies Disease Progression Humans Italy Leukemia Myelogenous Chronic BCR-ABL Positive Philadelphia Chromosome Pneumonia Viral Pyrazoles SARS-CoV-2 Severity of Illness Index Survival Analysis PandemicsPandemicsPhiladelphia negativebusiness.industrySARS-CoV-2Disease progressionCOVID-19Hematologymedicine.diseaseSurvival AnalysisCross-Sectional StudiesPyrimidinesItalyOncologyDisease ProgressionPyrazolesbusinessCoronavirus InfectionsCoronavirus InfectionsLeukemia
researchProduct